SGO2

Chr 2q33.1

shugoshin 2

Aliases:: TRIPIN, FLJ25211
MANE:: ENST00000357799.9

OMIM: 612425 ↗NCBI: 151246 ↗Ensembl ↗

Annotations refreshed 9 hours ago.

Predicted protein structure

AlphaFold predicted structure

SGO2 · Q562F6

v62025-08-01

Predicted Aligned Error matrix for SGO2 — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

42.8/ 100

Very low

1,265 residues

Confidence breakdown

Very high(≥ 90)6%
Confident(70–90)3%
Low(50–70)5%
Very low(< 50)87%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Moderate Evidence (Amber)

Primary ovarian insufficiency
BIALLELIC, autosomal or pseudoautosomal

Disease associations (Open Targets)

nodular goiter
0.43
primary ovarian failure
0.34
multinodular goiter
0.29
nontoxic goiter
0.29
myasthenia gravis
0.26
Perrault syndrome
0.19
hepatocellular carcinoma
0.10
glioma
0.08
central nervous system cancer
0.08
breast cancer
0.08

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Shugoshin 2

Cooperates with PPP2CA to protect centromeric cohesin from separase-mediated cleavage in oocytes specifically during meiosis I. Has a crucial role in protecting REC8 at centromeres from cleavage by separase. During meiosis, protects centromeric cohesion complexes until metaphase II/anaphase II transition, preventing premature release of meiosis-specific REC8 cohesin complexes from anaphase I centromeres. Is thus essential for an accurate gametogenesis. May act by targeting PPP2CA to centromeres, thus leading to cohesin dephosphorylation (By similarity). Essential for recruiting KIF2C to the inner centromere and for correcting defective kinetochore attachments. Involved in centromeric enrichment of AUKRB in prometaphase